| Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 21031343 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Vaspin, adiponectin and interleukin-6 (IL-6) constitute novel adipose-tissue derivatives, known as adipokines, which mediate insulin resistance. The aim of the present study was to evaluate the effects of metformin and rosiglitazone on serum levels of those novel adipokines in drug-naïve patients with type 2 diabetes mellitus (T2DM). METHODS: 140 patients with T2DM, already treated with diet, but without adequate glycemic control (HbA1c > 7%), were randomly assigned to: RSG+MET group, (n = 70): Combination therapy with fixed dose of 4 mg rosiglitazone plus 500 mg metformin. MET group, (n = 70): Half-maximum dose of metformin monotherapy (1 700 mg/day). Before and after 6-month treatment, body-mass index (BMI), blood pressure (BP), fat-mass, fasting plasma glucose (FPG), HbA1c, insulin resistance indexes (HOMA-IR, insulin), lipids, high-sensitivity CRP (hsCRP), vaspin, adiponectin, and interleukin-6 (IL-6) were measured. RESULTS: Glucose regulation and insulin resistance were equivalently improved from baseline within both groups (p < 0.05). There was a considerable amelioration of hsCRP, WBC, adiponectin, IL-6, systolic and diastolic BP with rosiglitazone/metformin combined treatment as compared to baseline (p < 0.05) and MET group (p < 0.05). In contrast, metformin monotherapy significantly reduced BMI (p < 0.001), total-cholesterol (p = 0.012) and LDL (p = 0.020) levels compared to RSG+MET group. Importantly, serum vaspin concentration was equivalently decreased from baseline in both RSG+MET (-0.96 ± 0.75 ng/ml, p < 0.001) and MET (-0.92 ± 0.57 ng/ml, p=0.001) group. The aforementioned vaspin changes correlated with changes in WHR, HbA1c, FPG, HOMA-IR, insulin, IL-6 (only in the RSG+MET group) and fat-mass. In standard multiple regression analysis, FPG, HbA1c, HOMA-IR and insulin remained independent determinants of serum vaspin levels changes (R² = 0.836, p = 0.004). CONCLUSIONS: Both rosiglitazone/metformin combination therapy and metformin monotherapy decreased serum vaspin levels through glucose and insulin sensitivity regulation, while they exerted differential effects on adiponectin, IL-6 and other cardiovascular risk factors in drug-naïve patients with T2DM. |
| | |
Authors:
|
N P E Kadoglou; A Kapelouzou; H Tsanikidis; I Vitta; C D Liapis; N Sailer |
Related Documents
:
|
1936483 - Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary... 6378583 - Oral hypoglycaemic agents. an update. 21355053 - Risk for esrd in type 1 diabetes remains high despite renoprotection. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-10-28 |
Journal Detail:
|
Title: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Volume: 119 ISSN: 1439-3646 ISO Abbreviation: Exp. Clin. Endocrinol. Diabetes Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-02-11 Completed Date: 2011-06-02 Revised Date: 2012-04-09 |
Medline Journal Info:
|
Nlm Unique ID: 9505926 Medline TA: Exp Clin Endocrinol Diabetes Country: Germany |
Other Details:
|
Languages: eng Pagination: 63-8 Citation Subset: IM |
Copyright Information:
|
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York. |
Affiliation:
|
First Department of Internal Medicine, Hippokratio General Hospital of Thessaloniki, Greece. nikoskad@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adiponectin
/
blood Aged Blood Glucose / analysis Diabetes Mellitus, Type 2 / blood*, drug therapy* Dose-Response Relationship, Drug Drug Combinations Female Humans Hypoglycemic Agents / administration & dosage Insulin Resistance / physiology Interleukin-6 / blood* Lipids / blood Male Metformin / administration & dosage*, pharmacology Middle Aged Neoadjuvant Therapy Serpins / blood* Thiazolidinediones / administration & dosage*, pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/ADIPOQ protein, human; 0/Adiponectin; 0/Blood Glucose; 0/Drug Combinations; 0/Hypoglycemic Agents; 0/IL6 protein, human; 0/Interleukin-6; 0/Lipids; 0/SERPINA12 protein, human; 0/Serpins; 0/Thiazolidinediones; 122320-73-4/rosiglitazone; 657-24-9/Metformin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expression of matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated with a pr...
Next Document: Depressive Symptoms, not Completing a Depression Screening Questionnaire, and Risk of Poor Complianc...